# EDGAR Filing Document

**Accession Number:** 0001267602
**File Stem:** 0001267602-23-000006
**Filing Date:** 2023-3
**Character Count:** 12990
**Document Hash:** 14ca46d7fc3779de14772659e048bcb4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001267602-23-000006.hdr.sgml**: 20230301

**ACCESSION NUMBER**: 0001267602-23-000006

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230224

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230301

**DATE AS OF CHANGE**: 20230301

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALIMERA SCIENCES INC
- **CENTRAL INDEX KEY:** 0001267602
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 200028718
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34703
- **FILM NUMBER:** 23694423

**BUSINESS ADDRESS:**
- **STREET 1:** 6310 TOWN SQUARE
- **STREET 2:** SUITE 400
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30005
- **BUSINESS PHONE:** 678-990-5740

**MAIL ADDRESS:**
- **STREET 1:** 6310 TOWN SQUARE
- **STREET 2:** SUITE 400
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30005

?xml version="1.0" encoding="utf-8"? alim-20230224x8k

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT** 

**PURSUANT TO SECTION 13 OR 15(D) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): February 24, 2023

## ALIMERA SCIENCES, INC.
(Exact name of registrant as specified in its charter)

---

| | | | |
|:---|:---|:---|:---|
| **Delaware** | **001-34703** | **001-34703** | **20-0028718** |
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (Commission File Number) | (IRS Employer Identification No.) |
| **6310 Town Square, Suite 400**<br>**Alpharetta, Georgia** | **6310 Town Square, Suite 400**<br>**Alpharetta, Georgia** | **30005**  | **30005**  |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) | (Zip Code) |

---

Registrant's telephone number, including area code: **(678) 990-5740**

---

| |
|:---|
| **Not Applicable** |
| (Former name or former address if changed since last report.) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| &nbsp;&nbsp;Title of each class | &nbsp;&nbsp;Name of each exchange on which registered |
| &nbsp;&nbsp;Common Stock, $0.01 par value per share<br> &nbsp;&nbsp;ALIM | &nbsp;&nbsp;The Nasdaq Stock Market LLC<br>(Nasdaq Global Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

**(b) Director Decision to Resign**

On February 24, 2023, Dr. Brian K. Halak notified Alimera Sciences, Inc. (the "Company") that he had decided to resign from the Company's Board of Directors (the "Board"), effective upon the appointment of Dr. Roger Sawhney to the Board, which occurred on February 25, 2023 as described below. Dr. Halak served as a director of the Company from 2004 until his resignation and he served as a member of the audit committee and the nominating and corporate governance committee of the Board. Dr. Halak's decision was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the Company's operations, policies, or practices. The Company greatly appreciates Dr. Halak's long and dedicated service as a director and wishes him the best in his future endeavors.

**(d) Appointment of New Director**

Dr. Sawhney has served as Chief Financial Officer of Garuda Therapeutics, Inc., a company creating off-the-shelf, durable blood stem cell therapies, since September 2022. From May 2020 to May 2022, Dr. Sawhney served as the Chief Financial Officer of Omega Therapeutics, Inc., a pioneer in mRNA-based therapeutics for precision gene modulation, and he served as the Chief Business Officer of Omega from May 2022 to September 2022. From September 2018 to February 2020, Dr. Sawhney served at KKR & Co. Inc., a global investment firm, as Director of its healthcare investment platform in the Americas where his work focused on investments across private and growth equity in the healthcare sector. From August 2009 to August 2012, Dr. Sawhney served as Senior Vice President and Head of Global Corporate Strategy for Novartis AG (NYSE: NVS), as well as Senior Vice President of Corporate Strategy and Business Development for Outcome Health from February 2017 to February 2018. Dr. Sawhney has also served as Partner with Bain & Company from August 2012 to February 2017 and the Boston Consulting Group from 1996 to 2009, where he managed numerous client engagements across the life sciences, med-tech and digital health sectors. Dr. Sawhney holds an M.D. from Harvard Medical School and a B.A. in Economics from Stanford University.

In connection with his election to the Board and pursuant to the Company's non-employee director compensation program (the "Director Compensation Program"), the Compensation Committee of the Board granted to Dr. Sawhney options to purchase 2,252 shares of the Company's common stock at an exercise price of $2.2092, the closing price per share of the common stock on February 27, 2023, the first trading date after his appointment to the Board. The options will vest and become exercisable in equal monthly installments of 450 shares on the 12th day of each month from March 12, 2023 through July 12, 2023, with the final installment to be adjusted as necessary to avoid any fractional shares in any installment, provided Dr. Sawhney provides continuous service to the Company through the applicable vesting date. In the event of a change of control of the Company or if Dr. Sawhney's service terminates due to his death or disability, the options will accelerate and immediately become exercisable. Also pursuant to the Director Compensation Program, Dr. Sawhney will receive a $40,000 annual retainer for his service on the Board, a $10,000 annual retainer for his service on the Audit Committee and a $4,000 annual retainer for his service on the Nominating and Governance Committee, with such retainers initially to be prorated to the 2023 annual meeting of stockholders. In addition, under the Director Compensation Program he will be eligible to receive, upon the conclusion of each annual meeting of stockholders beginning in 2023, options to purchase an additional 6,000 shares of the Company's common stock, provided he is then continuing to serve on the Board.

Dr. Sawhney and the Company will also enter into an indemnification agreement requiring the Company to indemnify him to the fullest extent permitted under Delaware law with respect to his service as a director. The indemnification agreement will be in the form the Company has entered into with its other directors and executive officers. This form is filed as Exhibit 10.1 to the Company's Registration Statement on Form S-1 (SEC File No. 333-162782), as filed with the SEC on October 30, 2009.

------

There are no arrangements or understandings between Dr. Sawhney and any other person pursuant to which he was appointed as a director. There are no transactions in which Dr. Sawhney has or will have an interest that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

**Item 7.01. Regulation FD Disclosure**

On February 27, 2023, the Company issued a press release announcing the appointment of Dr. Sawhney to the Board. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 **‎** 

------

**Item 9.01. Financial Statements and Exhibits.**

(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| 99.1 | [<u>Press Release of Alimera Sciences, Inc. dated February 27, 2023</u>](alim-20230224xex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

 **‎** 

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | ALIMERA SCIENCES, INC. | ALIMERA SCIENCES, INC. |
| Dated: March 1, 2023 | By: | /s/ Russell L. Skibsted |
|  | Name: | Russell L. Skibsted |
|  | Title: | Chief Financial Officer and Senior Vice President |

---

## Exhibit 99.1

**Exhibit 99.1**

![A picture containing text Description automatically generated](alim-20230224xex99_1g001.jpg)

**FOR IMMEDIATE RELEASE**

**Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors** 

ATLANTA (February 27, 2023) – Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Roger Sawhney, M.D. to its Board of Directors. Dr. Sawhney is presently the Chief Financial Officer for Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies. Dr. Sawhney will fill the position vacated by long term board member, Dr. Brian K. Halak.

"Dr.Sawhney brings a richness of financial experience both from the pharma corporate and healthcare investment points of view," said Rick Eiswirth, Alimera's President and Chief Executive Officer. "His insights and expertise will prove to be valuable behind our vision to become the place to be in retina."

"I am excited to join Alimera at this point in their history with ILUVIEN continuing to show significant growth and the enrollment of the NEW DAY study nearing completion," added Dr. Sawhney. "I believe that I can bring some additional experience to the board that will help with Alimera's continued growth."

Dr. Sawhney has served as Chief Financial Officer of Garuda Therapeutics, Inc, since September 2022. From May 2020 to May 2022, Dr. Sawhney served as the Chief Financial Officer of Omega Therapeutics, Inc. (Nasdaq: OMGA), a pioneer in mRNA-based therapeutics for precision gene modulation, and he served as the Chief Business Officer of Omega from May 2022 to September 2022.

From September 2018 to February 2020, Dr. Sawhney served at KKR & Co. Inc. (NYSE: KKR), a global investment firm, as Director of its healthcare investment platform in the Americas where his work focused on investments across private and growth equity in the healthcare sector. From August 2009 to August 2012, Dr. Sawhney served as Senior Vice President and Head of Global Corporate Strategy for Novartis AG (NYSE: NVS), as well as Senior Vice President of Corporate Strategy and Business Development for Outcome Health from February 2017 to February 2018. Dr. Sawhney has also served as Partner with Bain & Company from August 2012 to February 2017

------

and the Boston Consulting Group from 1996 to 2009, where he managed numerous client engagements across the life sciences, med-tech and digital health sectors.

Dr. Sawhney holds an M.D. from Harvard Medical School and a BA in Economics from Stanford University.

**About Alimera Sciences, Inc.**

Alimera Sciences a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

**For press inquiries:For investor inquiries:**

Jules AbrahamScott Gordon

for Alimera Sciences for Alimera Sciences

917-885-7378scottg@coreir.com

julesa@coreir.com

\# \# \#

------